Published in Medicine and Law Weekly, July 27th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Genmab A/S.
Report 1: Genmab A/S (CSE: GEN) announced that development plans for ofatumumab (HuMax-CD20(R)) will be described at GlaxoSmithKline's (GSK) Oncology Seminar today. Ofatumumab is currently in late stage development for chronic lymphocytic leukemia (CLL), follicular non-Hodgkin's lymphoma (NHL) and in Phase II for rheumatoid arthritis (RA) and is being developed under a worldwide co-development and commercialisation agreement between Genmab and GSK.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly